ITCI vs. IONS, GRFS, CTLT, ISEE, ASND, CERE, ROIV, OGN, ALKS, and MDGL
Should you be buying Intra-Cellular Therapies stock or one of its competitors? The main competitors of Intra-Cellular Therapies include Ionis Pharmaceuticals (IONS), Grifols (GRFS), Catalent (CTLT), IVERIC bio (ISEE), Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Roivant Sciences (ROIV), Organon & Co. (OGN), Alkermes (ALKS), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "pharmaceutical preparations" industry.
Intra-Cellular Therapies vs.
Ionis Pharmaceuticals (NASDAQ:IONS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.
Ionis Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.
Intra-Cellular Therapies has lower revenue, but higher earnings than Ionis Pharmaceuticals. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Ionis Pharmaceuticals has a net margin of -56.85% compared to Intra-Cellular Therapies' net margin of -73.46%. Intra-Cellular Therapies' return on equity of -33.92% beat Ionis Pharmaceuticals' return on equity.
Ionis Pharmaceuticals received 182 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. However, 66.81% of users gave Intra-Cellular Therapies an outperform vote while only 60.39% of users gave Ionis Pharmaceuticals an outperform vote.
In the previous week, Intra-Cellular Therapies had 2 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 11 mentions for Intra-Cellular Therapies and 9 mentions for Ionis Pharmaceuticals. Intra-Cellular Therapies' average media sentiment score of 0.67 beat Ionis Pharmaceuticals' score of 0.60 indicating that Intra-Cellular Therapies is being referred to more favorably in the news media.
87.3% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 87.0% of Intra-Cellular Therapies shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 3.4% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Ionis Pharmaceuticals currently has a consensus price target of $46.64, indicating a potential upside of 14.73%. Intra-Cellular Therapies has a consensus price target of $74.82, indicating a potential upside of 13.67%. Given Ionis Pharmaceuticals' higher probable upside, equities research analysts clearly believe Ionis Pharmaceuticals is more favorable than Intra-Cellular Therapies.
Summary
Intra-Cellular Therapies beats Ionis Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ITCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intra-Cellular Therapies Competitors List
Related Companies and Tools
